Please Scroll Down to See Forums Below 
b1ewsw32
New member
Has any member had experience with Zofran(Ondansetron)..a unique nootropic found to increase acetylcholine levels, but only in those areas of the brain which are concerned with memory.
I came across an interesting article supporting possible remediation of OCD due to it's ability to antagonize the 5HT3 receptor.
This same receptor is responsible for nausea associated with initial SSRI therapy, but then dissipates in time for most users.
It's original indication is used to treat chemo-therapy induced nausea via it's 5HT3 blocking properties.
Ondansetron shows OCD promise
Low-dose ondansetron may be promising as a monotherapy for some patients suffering from obsessive-compulsive disorder (OCD), findings from a pilot study suggest.
Ondansetron is a 5-HT3 receptor antagonist, and these agents have been found to act as anxiolytics in selected animal models of anxiety, particularly those involving an element of risk assessment.
Since the compulsions of OCD are frequently triggered by abnormal perception of risk, William Hewlett and colleagues, from Vanderbilt University School of Medicine in Nashville, Tennessee, USA, carried out a preliminary study to determine the efficacy of odanestron for the treatment of the disorder.
They assessed eight patients with OCD, none of whom were receiving medication. The participants were treated with ondansetron at a fixed dose of 1 mg three times a day for 8 weeks.
In total, six patients completed the trial. Of these, three (37%) achieved a clinically significant response, as indicated by a 35% or greater reduction in Yale Brown Obsessive-Compulsive Scale (YBOCS) score, with an average reduction in TBOCS-rated symptoms of 55%.
Altogether, the eight patients exhibited a 28% reduction in YBOCS-rated symptoms over the course of the trial, from an average baseline rating of 23.8.
In addition, among 6 patients available for follow-up 2 weeks after finishing treatment, there was a statistically significant increase in YBOCS scores, representing a 45% worsening of symptoms.
Based on the findings, the researchers conclude in the Journal of Clinical Psychiatry that ondansetron may be an effective monotherapy for OCD, and further trials "employing 5-HT3 antagnoists as adjuncts for both serotonin reuptake inhibitor and behavioural therapies may be warranted."
J Clin Psychiatry 2003; 64: 1025-1030
B32
I came across an interesting article supporting possible remediation of OCD due to it's ability to antagonize the 5HT3 receptor.
This same receptor is responsible for nausea associated with initial SSRI therapy, but then dissipates in time for most users.
It's original indication is used to treat chemo-therapy induced nausea via it's 5HT3 blocking properties.
Ondansetron shows OCD promise
Low-dose ondansetron may be promising as a monotherapy for some patients suffering from obsessive-compulsive disorder (OCD), findings from a pilot study suggest.
Ondansetron is a 5-HT3 receptor antagonist, and these agents have been found to act as anxiolytics in selected animal models of anxiety, particularly those involving an element of risk assessment.
Since the compulsions of OCD are frequently triggered by abnormal perception of risk, William Hewlett and colleagues, from Vanderbilt University School of Medicine in Nashville, Tennessee, USA, carried out a preliminary study to determine the efficacy of odanestron for the treatment of the disorder.
They assessed eight patients with OCD, none of whom were receiving medication. The participants were treated with ondansetron at a fixed dose of 1 mg three times a day for 8 weeks.
In total, six patients completed the trial. Of these, three (37%) achieved a clinically significant response, as indicated by a 35% or greater reduction in Yale Brown Obsessive-Compulsive Scale (YBOCS) score, with an average reduction in TBOCS-rated symptoms of 55%.
Altogether, the eight patients exhibited a 28% reduction in YBOCS-rated symptoms over the course of the trial, from an average baseline rating of 23.8.
In addition, among 6 patients available for follow-up 2 weeks after finishing treatment, there was a statistically significant increase in YBOCS scores, representing a 45% worsening of symptoms.
Based on the findings, the researchers conclude in the Journal of Clinical Psychiatry that ondansetron may be an effective monotherapy for OCD, and further trials "employing 5-HT3 antagnoists as adjuncts for both serotonin reuptake inhibitor and behavioural therapies may be warranted."
J Clin Psychiatry 2003; 64: 1025-1030
B32
